header image

Noticias Recientes

Octapharma wins major tender victory in Norway

21.12.2012

LACHEN, Switzerland (20th December 2012)  Octapharma was recently awarded an extension of the exclusivity contract for virus inactivated plasma, Octaplas, with all Norwegian hospitals for four more years. Today Norway...

Octapharma opens €25 million recombinant research facility in Heidelberg

27.09.2012

LACHEN, Switzerland (28th September, 2012) – Octapharma AG today announces the opening of a €25 million research facility dedicated to recombinant protein drug development in Heidelberg, Germany. Octapharma...

Octapharma hosts symposium at WFH World Congress on meeting the challenges of von Willebrand Disease (VWD) diagnosis and treatment

23.07.2012

LACHEN, Switzerland (July, 23, 2012) − Octapharma AG, a leading producer of human proteins for life saving therapies, sponsored the symposium entitled “Meeting the challenges of VWD diagnosis and treatment- Which problems...

Octapharma hosts symposium at WFH World Congress on “Personalizing the Inhibitor Treatment and Prevention” in haemophilia A

20.07.2012

LACHEN, Switzerland (July 20th, 2012) – Octapharma AG, a leading producer of human proteins for life saving therapies, proudly sponsored an octanate® symposium entitled “Personalizing the Inhibitor Treatment and Prevention: New...

Octapharma is presenting two scientific symposia on Immune Tolerance Induction in Haemophilia A and von Willebrand Disease at World Federation of Haemophilia World Congress 2012 in Paris

05.07.2012

Octapharma AG announces the sponsorship of two scientific symposia during the 2012 World Congress of World Federation of Haemophilia (WFH) held in Paris from July 8 -12, 2012. Octapharma is a leading producer of human proteins...

Octapharma USA expands access to octagam® 5% for participating 340B healthcare facilities

26.06.2012

Initiative Focuses on Providing IGIV to Underserved Patients

Octapharma Group releases 2011 Annual Report

30.03.2012

2011 has been a successful transitional year for the Octapharma Group. Since octagam® 5% and 10% re-entered all important markets profitability experienced a month-by-month continuous improvement. Re-entry combined with the...

Muestra Resultados de 1 a 7 9